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The Human Genome Project and advances in DNA sequencing technologies have revolutionized the
identification of genetic disorders through the use of clinical exome sequencing. However, in a considerable
number of patients, the genetic basis remains unclear. As clinicians begin to consider whole-genome
sequencing, an understanding of the processes and tools involved and the factors to consider in the
annotation of the structure and function of genomic elements that might influence variant identification is
crucial. Here, we discuss and illustrate the strengths and weaknesses of approaches for the annotation and
classification of important elements of protein-coding genes, other genomic elements such as pseudogenes
and the non-coding genome, comparative-genomic approaches for inferring gene function, and new
technologies for aiding genome annotation, as a practical guide for clinicians when considering pathogenic
sequence variation. Complete and accurate annotation of structure and function of genome features has the
potential to reduce both false-negative (from missing annotation) and false-positive (from incorrect
annotation) errors in causal variant identification in exome and genome sequences. Re-analysis of unsolved
cases will be necessary as newer technology improves genome annotation, potentially improving the rate of
diagnosis.Background
Advances in genomic technologies over the past 20 years
have provided researchers with unprecedented data re-
lating to genome variation in different diseases [1]. How-
ever, even after whole-exome sequencing (WES), the
genetic basis for a particular phenotype remains unclear
in a considerable proportion of patients. Here, we exam-
ine how genomic annotation might influence variant
identification, using examples mostly from both com-
mon and rarer neurological disorders. We highlight why
the present technology can fail to identify the pathogenic
basis of a patient’s disorder, or produce an incorrect re-
sult where the wrong variant is labelled as causative. For
these reasons, we believe it is important to re-analyse
unresolved cases as newer technology and software im-
prove gene and genome annotation. The aim of this* Correspondence: charles.steward@congenica.com
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ible to clinicians through the use of figures and examples
that help to explain genome sequencing, gene classifica-
tion and genome annotation in the context of patho-
genic sequence variation. Finally, we discuss how new
genomic techniques will improve our ability to identify
pathogenic sequence variation.Genome sequencing
The Human Genome Project (HGP) was launched offi-
cially in 1987 by the US Department of Energy to se-
quence the approximately 3 billion base-pairs (bp) that
constitute the human genome [2]. The first draft se-
quence was published in 2001 and computational anno-
tation, a process that attributes a biological function to
the genomic elements, described 30,000 to 40,000
protein-coding genes across 22 pairs of autosomes and
the X and Y sex chromosomes in a genome of 2.9 billion
bases (gigabases, Gb) [2]. The precise size and gene
count of the reference human genome remains uncertain
to this day because sequence gaps remain, while thele is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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Fig. 1 The genome analysis pipeline. Note that, for clarity, some steps
have been omitted. Figure illustrations are not to scale and are only
meant to be illustrative of the differences between short- and long-
read sequencing. a Unaligned reads from sequencing machines are
stored as FASTQ file formats. This is a text-based format for storing
both a DNA sequence and its corresponding quality scores. b Reads
are aligned to the genome. Short reads provide deep coverage,
whereas reads that have been sequenced from both ends (blue arrows)
help to orientate unaligned contigs. It is difficult to align short reads
confidently across repetitive sequences when the repeating genome
sequence is longer than the sequence read. Long-read sequences help
to order contigs across larger regions, particularly with repetitive
sequences, but do not provide the necessary depth needed to be
confident of calling a base at a certain position. Note that there is a
large region where there is no read coverage at all. This is indicative of
structural variation. Here, the patient has a large deletion with respect
to the reference genome. Once the reads have been aligned to the
reference genome they are stored in a BAM file. A BAM file (.bam) is
the binary version of a sequence alignment map (SAM file format). The
latter is a tab-delimited text-based format for storing DNA sequences
aligned to a reference sequence. c The Variant Call Format (VCF)
specifies the format of a text file used in bioinformatics for storing
genetic sequence variations. VCF files are much smaller than FASTQ
and BAM files. Note that single-nucleotide variants (SNVs) and small
insertions and deletions (‘indels’) are illustrated as red and purple blocks,
whereas a much larger structural variant is indicated by an
orange block
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quently, additions are continually made to the genome
to fill sequence gaps [4]. The most recent published esti-
mates suggest that just under 20,000 protein-coding
genes [5] are present in a genome of approximately 3.1
Gb [6]. The HGP enabled initial research examining se-
quence variation on chromosome 22 [7], to more recent
medical advances that now see DNA sequencing used
routinely in large-scale research programs, such as the
Deciphering Developmental Disorders (DDD) study [8,
9]. Sequencing for the HGP used the chain terminator
method [10], more commonly known as ‘Sanger sequen-
cing’, and owing to the better-quality sequence data and
read-length associated with Sanger sequencing com-
pared with current sequencing technologies, Sanger se-
quencing is still used to confirm sequence variants [11].
Current methods for producing the raw sequence data
for whole-genome sequencing (WGS) are placed into two
categories based upon the length of the nucleotide se-
quence produced, or sequence ‘read’. Short-read technology
comes from Illumina Inc. [12] and uses well-established
chemistry to identify the sequence of nucleotides in a given
short segment of DNA. Illumina sequencing platforms such
as the HiSeq X produce base-pair reads of lengths from
150 to 250 bp in a given DNA segment and are used to
read sequences from both ends of a DNA fragment. This
‘next-generation’ technology is a dramatic improvement
over older Sanger sequencing methods that produced lon-
ger reads but at much higher cost [13]. More recently,
‘third-generation’ technologies from Pacific Biosciences
(PacBio) and Oxford Nanopore are gaining users and mak-
ing an impact. These third-generation methods generate
longer reads, up to tens of thousands of base-pairs per read,
but with higher error rates.
The speed of DNA sequencing, the amount of se-
quence that can be produced and the number of ge-
nomes that can be sequenced have increased massively
with next-generation sequencing (NGS) techniques
[14]. Such advances have enabled large collaborative
projects that look at variation in a population, such as
the 1000 Genomes Project [15], as well as those investi-
gating the medical value of WGS, such as the UK
100,000 Genomes Project [16]. It is hoped that WGS
will facilitate the research, diagnosis and treatment of
many diseases.
Once a patient genome has been sequenced, it needs
to be aligned to the reference genome and analysed for
variants. Typically, software algorithms such as the
Burrows-Wheeler Aligner (BWA) are used for short-
[17] and long-read [18] alignment and the Genome Ana-
lysis Toolkit (GATK) is used to identify or ‘call’ sequence
variants [19]. Figure 1 illustrates a typical genome ana-
lysis pipeline, describing the different file formats com-
monly used—FASTQ [20], BAM [21] and VCF [22].Pathogenic sequence variation can range in size from
single-nucleotide variants (SNVs), small insertions and
deletions (‘indels’) of fewer than 50 base-pairs in length,
to larger structural variants (SVs) [23], which are gener-
ally classified as regions of genomic variation greater
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tions, retrotransposon elements, inversions, segmental
duplications, and other such genomic rearrangements
[24, 25]. Currently, the consequence of non-synonymous
variants of the protein-coding elements only can be rou-
tinely automatically predicted by algorithms such as
SIFT and PolyPhen [26], yet many different types of vari-
ants are implicated in disease. As sequencing techniques
begin to move away from ‘gene panel’ testing to WGS, it
is crucial to understand the structure of genes and any
regulatory features that might lie within intra/intergenic
regions as changes in any of these regions might have a
crucial impact on the function of a gene.
Recently, the American College of Medical Genetics
and Genomics (ACMG) recommended a set of stan-
dards and guidelines to help medical geneticists assign
pathogenicity using standardized nomenclature and
evidence used to support the assignment for Mendel-
ian disorders [27]. For example, the terms ‘mutation’
and ‘polymorphism’ have often been used mislead-
ingly, with assumptions made that ‘mutation’ is patho-
genic, whereas ‘polymorphism’ is benign. As such, one
recommendation that ACMG makes is that both these
terms are replaced by ‘variant’, with the following
modifiers (1) pathogenic, (2) likely pathogenic, (3) un-
certain significance, (4) likely benign, or (5) benign
[27]. As such, here, we use the term variant. A stand-
ard gene-variant nomenclature is maintained and ver-
sioned by the Human Genome Variation Society
(HGVS) [28]. Both ACMG and HGVS examples are il-
lustrated in Table 1.Table 1 Examples of disease-causing variation with associated HGVS
Location Gene Variation HGVS nomenclature ACM
sign
5′ UTR FMR1 Expansion NM_002024.5(FMR1):c.-128_-
126(200)
Path
CDS GRIN2A Nonsense NM_000833.4(GRIN2A):c.2041C > T
(p.Arg681Ter)
Path
CDS GABRB3 Missense NM_021912.4(GABRB3):c.745C >
A (p.Gln249Lys)
Path
CDS WDR62 Deletion/
frameshift
NM_001083961.1(WDR62)
:c.3839_3855del17 (p.Gly1280Alafs)
Path
3′ UTR MECP2 SNV NM_004992.3(MECP2):c.*2956G > A Unce
sign
Promoter CRH SNV NC_000008.11:g.66178947G > T Path
Splice
site
ATP6AP2 SNV NM_005765.2(ATP6AP2):c.321C >
T (p.Asp107=)
Path
Poly(A) ARSA SNV NM_000487.5(ARSA):c.*96A > G Path
NMD SNRPB SNV NM_003091.3(SNRPB):c.-72C > A Path
lncRNA ATXN8OS Insertion NR_002717.2(ATXN8OS)
:n.1103_1105CTG(15_40)
Path
ACMG American College of Medical Genetics and Genomics, CDS coding sequence,
nonsense-mediated decay, SNV single-nucleotide variant, UTR untranslated regionClassifying genes and other genomic elements
Current gene sets identify under 20,000 protein-coding
genes and over 15,000 long non-coding RNAs (lncRNAs)
[29, 30]. In this section, for clinicians who might not be fa-
miliar with gene structure and function, we present the
important elements of different parts of protein-coding
genes, and other categories of genomic elements, such as
pseudogenes and elements of the non-coding genome
such as lncRNAs, and we highlight their potential func-
tionality, illustrated with examples of their roles in disease.
We demonstrate the importance of classifying such re-
gions correctly and why incorrect classification could im-
pact the interpretation of sequence variation.
Important elements of protein coding genes
A eukaryotic gene is typically organized into exons and in-
trons (Fig. 2), although some genes, for example SOX3,
which is associated with X-linked mental retardation [31],
can have a single exon structure. The functional regions of
protein-coding genes are typically designated as the
coding sequence (CDS) and the 5′ and 3′ untranslated re-
gions (UTRs) (Fig. 2).
The 5′ UTR of a transcript contains regulatory regions.
For example, some upstream open reading frames
(uORFs; which are sequences that begin with an ATG
codon and end in a stop codon, meaning that they have
the potential to be translated) in the 5′ UTR are translated
to produce proteins that could enhance or suppress the
function of the main CDS [32]. Experimental techniques
such as cap-analysis gene expression (CAGE) [33] are
used to identify transcription start sites (TSSs) (Fig. 2a).nomenclature
G clinical
ificance
Associated disorder Reference
ogenic Fragile X syndrome [186]
ogenic Idiopathic focal epilepsy (IFE) with rolandic
spikes is the most common childhood epilepsy
[187]
ogenic Early infantile epileptic encephalopathy (EIEE) [188]
ogenic Malformations of cortical development [189]
rtain
ificance
Rett syndrome [190]
ogenic Familial autosomal dominant nocturnal frontal
lobe epilepsy
[191]
ogenic X-linked mental retardation and epilepsy due
to inefficient inclusion of exon 4
[192]
ogenic Metachromatic leukodystrophy [193]
ogenic Cerebro-costo-mandibular syndrome [194]
ogenic Spinocerebellar ataxia type 8 [195]
HGVS Human Genome Variation Society, lncRNA long non-coding RNA, NMD
ab
c
d
e
Fig. 2 The generic gene model (not to scale). a The exons comprise the untranslated regions (UTRs), which are shown in red (the 5′ UTR
depicted on the left and the 3′ UTR depicted on the right) and the coding sequence (CDS), which is shown in green. Many important regulatory
regions lie outside of the exons of a gene. Intronic regulatory regions are shown in grey. Promoters are illustrated as yellow intergenic regulatory
regions, although some genes have internal transcription start sites. The transcription start site (TSS) is positioned at the 5′ end of the UTR, where
transcription starts. The 5′ UTRs of genes contain regulatory regions. The CDS start codon is the first codon of a messenger RNA (mRNA) from
which a ribosome translates. The genomic sequence around the start codon often has the consensus sequence gccAcc|AUG|G (note that the
important bases are highlighted here in bold, whereas the most crucial positions are –3 and +4 from the A of the AUG) [197], although, in very
rare cases, a non-AUG start codon is used [198]. The stop codon, of which there are three in eukaryotes—UGA, UAG, UAA—is a nucleotide triplet
sequence in an mRNA that gives the signal to terminate translation by binding release factors, causing the ribosome to release the peptide chain
[199]. The 3′ untranslated region of genes contains regulatory regions. In particular, the 3′ UTR has binding sites for regulatory proteins such as
RNA-binding proteins (RBP) and microRNAs (miRNA). Promoters are DNA sequences, between 100 and 1000 bp in length, where proteins that
help control gene transcription bind to DNA [200]. These proteins can contain one or more DNA-binding domains that attach to a specific DNA
sequence located next to the relevant gene [201]. Promoters regulate transcriptional machinery by moving it to the right place in the genome,
as well as locating the 5′ end of the gene or an internal transcription start site. Approximately 40% of human genes have promoters situated in
regions of elevated cytosine and guanine content, termed CpG islands [202]. A subset of promoters incorporate the variable TATA box sequence
motif, which is found between 25 and 30 bp upstream of the TSS and is the position at the 5′ end of the UTR where transcription starts [203]. b–
d Pre-mRNA transcribed from DNA contains both introns and exons. An RNA and protein complex called the spliceosome undertakes the splicing
out of introns, leaving the constitutive exons. Intronic and exonic splice enhancers and silencers help direct this procedure, such as the branch
point (‘A’) and a poly-pyrimidine (poly-py) tract. The vast majority of introns have a GT sequence at the 5′ end that the branch point binds to. The
intron is then cleaved from the 5′ exon (donor site) and then from the 3′ exon (acceptor site) [204] and a phosphodiester bond joins the exons,
whereas the intron is discarded and degraded. During the formation of mature mRNA, the pre-mRNA is cleaved and polyadenylated. Polyadenylation
occurs between 10 and 30 bp downstream from a hexamer recognition sequence that is generally AAUAAA, or AUUAAA, although other hexamer
signal sequences are known [35] (as depicted in a). A specially modified nucleotide at the 5′ end of the mRNA, called the 5′ cap, helps with mRNA
stability while it undergoes translation. This capping process occurs in the nucleus and is a vital procedure that creates the mature mRNA. e The
translation of mRNA into protein by ribosomes occurs in the cytosol. Transfer RNAs (tRNAs), which carry specific amino acids, are read by the ribosome
and then bound in a complementary manner to the mRNA. The amino acids are joined together into a polypeptide chain to generate the complete
protein sequence for the coding sequence of the transcript. (Light blue background shading shows processes that occur in the nucleus. Light yellow
background shading shows processes that occur in the cytosol, such as the translation of mRNAs into protein by ribosomes)
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ied and understood area of pathogenic sequence vari-
ation. For example, approximately 700 pathogenic CDS
variants have been reported in the epilepsy-associated
gene SCN1A [34].
The 3′ UTR of a transcript can contain regions control-
ling regulatory proteins such as RNA binding proteins(RBPs) and microRNAs (miRNAs) (Fig. 2a). Interestingly,
the 3′ UTR has been linked to overall translation effi-
ciency and stability of the mRNA [35]. The 5′ and 3′
UTRs can also interact with each other to regulate
translation through a closed-loop mechanism [36]. Im-
portant sequence motifs involved in controlling the ex-
pression of a gene include promoters, enhancers and
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intergenic regions (Fig. 2a).
A multi-exonic eukaryotic gene can produce different
disease phenotypes through alternative protein isoforms
that result from the use of alternative splice site/exon
combinations (Fig. 3) [37]. Canonical splice sites are
generally conserved at the 5′ (donor) and 3′ (acceptor)
ends of vertebrate introns. The GT–intron–AG config-
uration is the most common, although other, rarer in-
stances of splice sites are found, such as GC–intron–AG
and AT–intron–AC [38].
Although there can be an abundant transcript that is
expressed in a particular cell, the same transcript might
not dominate elsewhere, and, even if a dominant tran-
script is identified, the transcript might not be functional
[39]. Differential expression can be both tissue- and age-
specific [40], can occur in response to different environ-
mental signals [41, 42], and an exon expressed in one
tissue might not be relevant to further analysis if it is
not expressed in the tissue where a disease phenotype is
present. For example, genes expressed in brain generally
have longer 3′ UTRs than those in other tissues, and
such differences could impact miRNA binding sites and
other regulatory regions [43]. Studies have shown that
retained introns have an important role in brain gene ex-
pression and regulation [44, 45].
Polyadenylation (poly(A)), which involves addition of
the poly(A) tail, is important for nuclear export to theFig. 3 Alternative splicing transcript variants. Different types of alternative s
nominal reference model. Red represents the untranslated region (UTR) and
illustrated as non-coding as a retained intron is presumed to represent an imma
exclusive (boxed). All the types of alternative exon splicing events shown here c
poly(A) features within the gene models, as seen for the skipped-exon transcripcytosol for translation by the ribosome and also helps
with mRNA stability (Fig. 2d). Many annotated genes
also have more than one poly(A) site, which can be func-
tional in different tissues or different stages of develop-
ment [42].
After translation, the polypeptide chain produced by
the ribosome might need to undergo posttranslational
modification, such as folding, cutting or chemical modi-
fications, before it is considered to be a mature protein
product (Fig. 2e). Noonan syndrome is believed to result
from the disruption of the phosphorylation-mediated
auto-inhibitory loop of the Src-homology 2 (SH2) do-
main during post-translational modification [46].
Transcripts that contain premature stop codons
(perhaps as a result of using an alternative splice
donor, splice acceptor, or inclusion/exclusion of an alter-
native exon, which causes a CDS frameshift) are degraded
through the nonsense-mediated decay (NMD) cellular
surveillance pathway (Fig. 4) [47, 48]. NMD was originally
believed to degrade erroneous transcripts, but much evi-
dence has been found to suggest it is also an active regula-
tor of transcription [49, 50]. Several NMD factors have
been shown to be important for the regulation of neuro-
logical events such as synaptic plasticity and neurogenesis
[51–53].
Two other types of cellular surveillance pathways are
known to exist: non-stop decay and no-go decay. Non-
stop decay is a process that affects transcripts that haveplicing can give rise to transcripts that are functionally distinct from a
green represents the coding sequence (CDS). The retained intron is
ture transcript. Some transcripts can contain exons that are mutually
an also occur in non-coding genes. There can also be multiple alternative
t
Fig. 4 The nonsense-mediated decay (NMD) pathway. Under normal
cellular circumstances, exon–exon junction complexes (EJCs) that are in
place after splicing are removed by the ribosome during the first round
of translation. However, when a transcript contains a premature
termination codon (PTC), perhaps as a result of an single-
nucleotide variant (SNV), indel or inclusion of an out-of-frame
exon upstream of one or more EJCs, these EJCs remain in place
because the ribosome complex disassociates at the premature
stop codon and thus cannot remove the downstream EJC. This
triggers the NMD pathway, and the transcript is degraded
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the CDS. The translation of such transcripts could pro-
duce harmful peptides with a poly-lysine amino acid se-
quence at the C-terminal end of the peptide—therefore,
these transcripts are subject to degradation. Similar toa b
Fig. 5 The processes involved in the ‘pseudogenisation’ of genes. a Proces
transcribed by the viral L1 repeat enzyme reverse-transcriptase and reinteg
pseudogenes are often flanked by direct repeats that might have some fun
missing sequence compared with their parent. Often they terminate in a se
the site of genomic integration. b Unprocessed pseudogenes—the defunc
duplications can be complete or partial with respect to the parent geneNMD transcripts, either aberrant splicing or SNVs can
cause the generation of these transcripts [54]. Finally,
no-go decay is triggered by barriers that block ribosome
movement on the mRNA [55].
The functional importance of pseudogenes
Pseudogenes are traditionally regarded as ‘broken’ cop-
ies of active genes. Freed of selective pressure, they
have typically lost the ability to encode functional pro-
teins through the occurrence of nonsense variations,
frameshifts, truncation events, or loss of essential regu-
latory elements. The majority of pseudogenes fall into
one of two categories: processed and unprocessed
(Fig. 5, Table 2) [56].
Processed pseudogenes represent back-integration or
retrotransposition of an RNA molecule into the genome
sequence, and, although they generally lack introns, they
frequently incorporate the remains of the poly(A) tail.
Processed pseudogenes are often flanked by direct re-
peats that might have some function in inserting the
pseudogene into the genome, and are often missing se-
quence compared with their parent gene (Fig. 5) [57]. By
contrast, unprocessed pseudogenes are defunct relatives
of functional genes that arise through faulty genomic du-
plication resulting in missing (parts of ) exons and/or
flanking regulatory regions (Fig. 5).sed pseudogenes are derived from mature mRNA that is reverse-
rated into the genome, and will generally lack introns. Processed
ction in inserting the pseudogene into the genome and they are often
ries of adenines, which are the remains of the poly(A) tail, which is
t relatives of functional genes—arise from genomic duplication. Such
Table 2 GENCODE annotation biotypes (2017)
Biotype Description
Protein coding Contains an ORF that has strong coding potential
Known coding 100% identical to known RefSeq protein or Swiss-Prot entry
Novel coding Shares >60% length with known coding sequence from RefSeq, or Swiss-Prot, or has cross-species/family
support or domain evidence
Putative coding Shares <60% length with known coding sequence from RefSeq, or Swiss-Prot, or has an alternative first or
last coding exon
Nonsense-mediated decay If the coding sequence (following the appropriate reference) of a transcript finishes >50 bp from a
downstream splice site, then it is tagged as NMD. If the variant does not cover the full reference coding
sequence, then it is
annotated as NMD if NMD is unavoidable—i.e. no matter what the exon structure of the missing portion
is, the transcript will be subject to NMD
Non-stop decay Transcripts that have poly(A) features (including signal) without a prior stop codon in the CDS—i.e. a
non-genomic poly(A) tail attached directly to the CDS without a 3′ UTR; these transcripts are subject to
degradation
Retained intron Alternatively spliced transcript believed to contain intronic sequence relative to other, coding, variants
Processed transcript Cannot assign an ORF, but is part of a coding locus
lncRNA Long non-coding RNA—lacks protein-coding potential and is of length >200 bp
Bidirectional promoter Transcription start sites of the lncRNA model and the protein-coding model are on opposite strands and
within 200 bp of one another, or are found in the same CpG island
3-Prime overlapping Transcription start site and/or published experimental data support independent transcription from the
3′ UTR of a coding gene
Antisense At least one variant overlaps a protein-coding locus on the opposite strand, or evidence of antisense
regulation of a coding gene has been published
lincRNA Long intergenic ncRNA: does not overlap (neither sense nor antisense) a coding gene
Sense intronic In an intron of a coding gene; no exonic overlap
Sense overlapping Contains a coding gene in an intron; no exonic overlap.
Pseudogene Matches to protein, but ORF disrupted by frameshifts and/or premature stop codons
Processed Lacks introns and arose from retrotransposition of parent gene mRNA
Unprocessed Can contain introns and is produced by genomic duplication
Transcribed Locus-specific transcripts indicate transcription; these can be classified into ‘processed’ and ‘unprocessed’
Translated Locus-specific protein mass spectroscopy data suggest translation; the connection is maintained with
the pseudogene biotype until the experimental community validates it as a coding gene
Polymorphic Pseudogene owing to a single-nucleotide variant (SNV), or insertion-deletion variant (indel); but the same
gene is translated in other individuals/haplotypes/strains
Unitary Species-specific unprocessed pseudogene, without a parent gene, that has an active orthologue in
another species
Data sourced from GENCODE project [196]
ncRNA noncoding RNA, ORF open reading frame, UTR untranslated region
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suffer from significant false positives/negatives and can
cause problems that result from the misalignment of
NGS data. Specifically, identification of transcribed pseu-
dogenes and single-exon pseudogenes can be a challenge
[58]. Such difficulties were demonstrated where it was
found that more than 900 human pseudogenes have evi-
dence of transcription, indicating functional potential
[58, 59]. Consequently, the ability to distinguish between
pseudogenes and the functional parent gene is essential
when predicting the consequence of variants.
MacArthur and colleagues [60] reported that reference
sequence and gene annotation errors accounted for44.9% of candidate loss-of-function (LoF) variants in the
NA12878 genome, which belongs to the daughter from
a trio of individuals belonging to the CEPH/Utah pedi-
gree whose genomes were sequenced to high depth as
part of the HapMap project [61]. The NA12878 genome
sequence and transformed cells from the same individual
(the GM12878 cell line) are often used as a reference in
other projects [62, 63]. After reannotation of protein-
coding genes harbouring 884 putative LoF variants, 243
errors in gene models were identified, 47 (19.3%) of
which were updated from protein-coding to pseudogene,
removing a significant source of false-positive LoF anno-
tation [60].
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have been shown to regulate the parent PTEN locus [64].
Deletion of PTENP1 has been reported to downregulate
PTEN expression in breast and colon cancer [64] and mel-
anoma [65], and downregulation of PTENP1 through
methylation of its promoter sequence in clear-cell renal cell
carcinoma suppresses cancer progression [66]. Although
PTENP1 has not yet been associated with any neuronal dis-
orders, both PTEN and PTENP1 are expressed in multiple
brain tissues [67, 68].The non-coding genome
Most of the genome is non-coding, and therefore most
variation occurs in non-coding regions. To understand
the effect of a sequence variant in such regions, the non-
coding elements need to be classified. Non-coding ele-
ments consist of cis-regulatory elements such as pro-
moters and distal elements (for example, enhancers) [69]
and non-coding RNAs (ncRNAs). Large collaborative
initiatives, such as ENCODE [63] and RoadMap Epige-
nomics [70], have been tasked to create comprehensive
maps of these regions. The Ensembl regulatory build
[71] and Variant Effect Predictor (VEP) [72] are able to
determine whether variants fall within such regions, but
are not yet able to determine pathogenicity, although
tools that do so are beginning to emerge, such as Fun-
Seq [73] and Genomiser [74].
The ncRNAs are generally divided into two groups,
small RNAs (sRNAs) and lncRNAs. sRNAs include miR-
NAs, Piwi-interacting RNAs (piRNAs), short interfering
RNAs (siRNAs), small nucleolar RNAs (snoRNAs) and
other short RNAs [75]. The sRNAs can be predicted using
tools such as Infernal [76] and Rfam [77], which makes
the interpretation of sequence variation and consequence
easier, especially when compared with the analysis of
lncRNAs. However, correctly discriminating functional
copies from pseudogenes remains a challenge.Fig. 6 Different classifications of long non-coding RNAs (lncRNAs). The clas
genes. lncRNAs are illustrated here with only red exons, whereas the codin
promoter, lincRNA long-intergenic RNA (not overlapping a protein-coding l
sense intronic. Figure adapted from Wright 2014 [84]Of particular interest to the study of neurological dis-
ease are microRNAs (miRNAs), which are small (approxi-
mately 20 nucleotides) ncRNAs that are involved in the
regulation of post-transcriptional gene expression [78].
miRNAs can trigger transcript degradation, modify trans-
lational efficiency and downregulate gene expression by
triggering epigenetic changes (DNA methylation and his-
tone modifications) at the promoter of target genes, and
are the best-understood of the ncRNAs. Studies have
shown that variants in miRNA binding sites are associated
with some neurological diseases, and there is evidence
for a role in epilepsy, suggesting that miRNAs might
be good candidates for the development of novel molecu-
lar approaches for the treatment of patients with epilepsy
[79, 80]. For example, miRNA MIR328 binds to the 3′
UTR of PAX6 to regulate its expression. However, vari-
ation in the miRNA binding site reduces the binding affin-
ity of MIR328, which in turn results in an increase in the
abundance of PAX6 transcripts, which is associated with
electrophysiological features of Rolandic epilepsy [81].
The EpiMiRNA consortium is investigating the role of
miRNAs in the development, treatment and diagnosis of
temporal lobe epilepsy [82].
The classification of lncRNAs is increasingly used to
convey functional information, despite the fact that we
know relatively little about the role or mechanism of the
vast majority of them (Fig. 6). The term lncRNA was itself
established to distinguish longer ncRNAs from the small
ncRNAs that were initially separated using an experimental
threshold of >200 nucleotides, which remains the simplest
definition of a lncRNA [63]. RNA sequencing (RNA-Seq)
assays predict that potentially tens, if not hundreds, of
thousands of lncRNA transcripts have now been identified
[83], which has inevitably led to the naming of many pro-
posed subclasses of lncRNA [84, 85]. Without any inter-
national agreement on the classification of lncRNAs,
proposed subclasses have been classified based on either
length, function, sequence or structural conservation, orsification of lncRNAs is based on their position with respect to coding
g genes are shown as red and green. AS antisense, BDP bi-directional
ocus on either strand), OS overlapping sense, O3′ overlapping 3′, SI
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ments, subcellular location or a particular biological state.
They are hard to predict owing to their size, but also be-
cause they are expressed at low levels and lack a known ter-
tiary structure, unlike miRNAs. A recent study by Nitsche
and colleagues showed that >85% of lncRNAs have con-
served splice sites that can be dated back to the divergence
of placental mammals [86].
lncRNAs, such as XIST [87], have been studied for some
time, yet little is known about the function of most. How-
ever, they are gaining interest within the scientific and
medical community [63] owing to their potential involve-
ment in disease [88, 89]. Experiments in mouse models
have demonstrated that dysregulation of certain lncRNAs
could be associated with epilepsy [90], and a role in gene
regulation is proposed for the vast number of unstudied
cases [91], which makes them interesting candidates for
new targeted therapies and disease diagnostics [92]. For
example, experiments in a knock-in mouse model of Dra-
vet syndrome have shown that the upregulation of the
healthy allele of SCN1A by targeting a lncRNA improved
the seizure phenotype [93].
CNVs also play an important role in human disease
and can affect multiple coding genes, resulting in dosage
effects, truncation of single genes or novel fusion prod-
ucts between two genes. CNVs have also been shown to
be pathogenic in non-coding regions [94]. Talkowski and
colleagues [95] observed a CNV causing disruption in
the long-intergenic non-coding RNA (lincRNA)
LINC00299 in patients with severe developmental delay,
raising the possibility that lincRNAs could play a signifi-
cant role in developmental disorders. More recently,
Turner et al. [96] reported WGS of 208 patients from 53
families with simplex autism and discovered small dele-
tions within non-coding putative regulatory regions of
DSCAM, implicated in neurocognitive dysfunction in
Down syndrome. These CNVs were transmitted from
the mother to the male proband.
Repetitive sequences and transposable elements are
known to be involved in disease and are believed to make
up more than two-thirds of the human genome. They also
have a strong association with genomic CNVs [97]. Long
interspersed nuclear elements (LINEs) and Alu repeats
(which are types of retrotransposons) have been associated
with increased genomic instability through non-allelic
homologous recombination events and can lead to patho-
genic duplications and deletions [98]. Alu–Alu repeat re-
combinations within the introns of ALDH7A1 have been
associated with pyroxidine-dependent epilepsy [99]. The
ability to accurately detect repetitive sequences is of great
importance due to the problems they can cause during
the aligning or assembling of sequence reads [100], and
the human genome is commonly analysed for repeats
using Repbase annotation [101] and computationalalgorithms, such as the hidden Markov model (HMM)-de-
rived database Dfam [102].
Genome annotation
The ability to understand the function of a gene and how
variation might affect its function is dependent upon un-
derstanding its structure, which can be elucidated by gen-
ome annotation. Genome annotation in its simplest form
proceeds by ab initio gene prediction algorithms that
search a genome for putative gene structures [103–105]
such as signals associated with transcription, protein-
coding potential and splicing [106]. Although these gene-
prediction algorithms were used in the early analysis of
the human genome [107, 108], they are limited in both
accuracy and coverage [29]. The current automated gene-
annotation tools, such as Ensembl, provide fast computa-
tional annotation of eukaryotic genomes using evidence
derived from known mRNA [109], RNA-Seq data [110]
and protein sequence databases [111].
Computational annotation systems are essential for
providing an overview of gene content in newly se-
quenced genomes and those with fewer resources
assigned to annotation, yet manual annotation is still
regarded as the ‘gold standard’ for accurate and compre-
hensive annotation (Table 3) [112]. As part of the EN-
CODE project, which was established to investigate all
functional elements in the human genome [113], a
genome-annotation assessment project was developed to
assess the accuracy of computational gene annotation
compared with a manually annotated test-set produced
by the Human and Vertebrate Analysis and Annotation
(HAVANA) team [29]. Although the best computational
methods identified ~70% of the manually annotated loci,
prediction of alternatively spliced transcript models was
significantly less accurate, with the best methods achiev-
ing a sensitivity of 40–45%. Conversely, 3.2% of tran-
scripts only predicted by computational methods were
experimentally validated.
Only two groups, HAVANA and Reference Sequence
(RefSeq) [30], produce genome-wide manual transcript
annotation. The HAVANA team is based at the Wellcome
Trust Sanger Institute, UK, and provides manual gene and
transcript annotation for high-quality, fully finished ‘refer-
ence’ genomes, such as that of human [3]. HAVANA man-
ual annotation is supported by computational and wet lab
groups who, through their predictions, highlight regions
of interest in the genome to be followed up by manual an-
notation, identify potential features missing from annota-
tion and experimentally validate the annotated transcripts,
then provide feedback to computational groups to help
improve the analysis pipelines.
The RefSeq collection of transcripts and their associated
protein products is manually annotated at the National
Center for Biotechnology Information (NCBI) in the USA.
Table 3 Comparison of computationally derived annotation versus manually derived annotation
Annotation procedure Automatic annotation—for example, Ensembl Manual annotation—for example, HAVANA
Genome analysis Very quick Very slow and labour intensive
Annotation consistency Consistent Risk of subjectivity—achieving consistency requires
careful training and monitoring
Sequence quality Flexible; can use unfinished, short-read NGS
sequence, shotgun assembly
Best results on high-quality sequence, but can offer
great insight into lower-quality assembly
Functional annotation Limited, lacking comprehensive detail of manual
annotation—frequently misassign related
sequences—i.e. protein-coding loci and pseudogenes
Extensive use of biotypes, such as coding, pseudogene,
lncRNA, NMD, etc.
Complex genomic regions Limited in ability to represent complex structures
and other nonstandard features
Superior representation and resolution of gene families
and able to define CDS regions of complicated gene
structures
Gene annotation Many false-positive and false-negative calls at locus
level in all gene biotypes
Better coverage of loci and alternatively spliced transcripts
Pseudogenes Limited Able to predict pseudogenes and differentiate from
genuine coding genes
Poly(A) features Limited Annotates poly(A) features
Flexibility Error prone, forces problems such as non-canonical
splicing and can only look at sequences more or
less in isolation
Deals with inconsistencies in data, consults literature and
other databases, can compare paralogues and orthologues
and rapidly integrate new sequencing technologies
CDS coding sequence, HAVANA Human and Vertebrate Analysis and Annotation, lncRNA long non-coding RNA, NGS next-generation sequencing, NMD
nonsense-mediated decay
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annotated, a significant proportion are not: for example in
NCBI Homo sapiens Annotation Release 106, approxi-
mately 45% of transcripts were classified as being computa-
tionally annotated [114]. Furthermore, unlike HAVANA
transcripts, which are annotated on the genome, RefSeq
transcripts are annotated independently of the genome and
based upon the mRNA sequence alone, which can lead to
difficulty mapping to the genome.
The GENCODE [58] gene set takes advantage of the
benefits of both manual annotation from HAVANA and
automated annotation from the Ensembl gene build
pipeline by combining the two into one dataset. GEN-
CODE describes four primary gene functional categories,
or biotypes: protein-coding gene, pseudogene, lncRNA
and sRNA. The adoption of further biotypes, at both the
gene level and transcript level, has enriched annotation
greatly (Table 2). The final gene set is overwhelmingly
manually annotated (~100% of all protein-coding loci
and ~95% of all transcripts at protein-coding genes are
manually annotated). Computational annotation predic-
tions of gene features are provided to give hints to man-
ual annotators and direct attention to unannotated
probable gene features, and are also used to quality con-
trol (QC) manual annotation to identify and allow cor-
rection of both false-positive and false-negative errors.
GENCODE and RefSeq collaborate to identify agreed
CDSs in protein-coding genes and to try and reach
agreement where there are differences as part of the col-
laborative Consensus CoDing Sequence (CCDS) project
[115, 116]. These CDS models, which do not include 5′or 3′ UTRs, are frequently used in exome panels along-
side the full RefSeq and GENCODE gene sets that form
the majority of the target sequences in exome panels.
The GENCODE gene set improves on the CCDS set
as it is enriched with additional alternatively spliced
transcripts at protein-coding genes as well as pseudo-
gene and lncRNA annotation, and as such is the most
detailed gene set [117]. GENCODE is now incorporated
into the two most widely used commercial WES kits
[118, 119], with fewer variants of potential medical im-
portance missed [120].
To present genome annotation in a meaningful and use-
ful manner, publicly available, web-based interfaces for
viewing annotation have been provided—for example, the
Ensembl Genome Browser [71] and the UCSC browser
[121] (Fig. 7), both of which display the GENCODE
models. The GENCODE genes are updated twice a year,
whereas CCDS is updated at least once a year. All tran-
scripts are assigned a unique stable identifier, which only
changes if the structure of the transcript changes, making
the temporal tracking of sequences easy.
A great deal of functionality is provided by genome
browsers, such as: displaying and interrogating gen-
ome information by means of a graphical interface,
which is integrated with other related biological data-
bases; identifying sequence variation and its predicted
consequence using VEP; investigating phenotype in-
formation and tissue-specific gene expression; and
searching for related sequences in the genome using
BLAST. Figure 7 presents by way of example the
gene KCNT1, which is associated with early infantile
ab
Fig. 7 Examples of genome browsers. a Screenshot of Ensembl genome browser showing the transcript splicing variants for the gene KCNT1
encoding a potassium channel subunit. Gold-coloured transcripts are those that are found by both manual and computational annotation. Black
transcripts are those that have been identified only through manual annotation. Blue transcripts are annotated without a coding sequence (CDS).
For example, the red arrow highlights an exon that causes a premature stop codon. This transcript has therefore been identified as being subject
to nonsense-mediated decay. b Screenshot of the UCSC genome browser also showing KCNT1. Comparison of, first, the basic GENCODE gene
annotation set (generally full-length coding transcripts based on full-length cDNAs) and, second, RefSeq manually curated genes, which generally
have fewer transcripts than GENCODE. The red boxes highlight novel transcription start site exons and novel internal exons that are not present
in RefSeq
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Ensembl and UCSC genome browsers.
Using comparative genomics to confirm gene
functionality
Sequence data from other organisms are essential for
interpreting the human genome owing to the functional
conservation of important sequences in evolution [123]
that can then be identified by their similarity [124]. The
zebrafish, for example, has a high genetic and physio-
logical homology to human, with approximately 70% of
human genes having at least one zebrafish orthologue.
This means that the zebrafish model can provide inde-
pendent verification of a gene being involved in human
disease. Zebrafish also develop very quickly and are
transparent, and so the fate, role and life cycle ofindividual cells can be followed easily in the developing
organism. This makes the zebrafish a highly popular ver-
tebrate model organism with which to study complex
brain disorders [125, 126], and it has been essential for
modelling disease in the DDD study [127].
Likewise, owing to a combination of experimental acces-
sibility and ethical concerns, the mouse is often used as a
proxy with which to study human disease [128, 129], and
this justified the production of a high-quality, finished, ref-
erence mouse genome sequence, similar to that of the hu-
man sequence [130]. Murine behavioural traits, tissues,
physiology and organ systems are all extremely similar to
those of human [131], and their genomes are similar too,
with 281 homologous blocks of at least 1 Mb [132] and
over 16,000 mouse protein-coding genes with a one-to-
one orthology to human [133]. The large number of
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many neurological diseases in patients [128], such as the
Q54 transgenic mouse used to study Scn2A seizure disor-
ders [134]. Recent studies in rodent models of epilepsy
have identified changes in miRNA levels in neural tissues
after seizures, which suggests that they could be key regu-
latory mechanisms and therapeutic targets in epilepsy
[135]. It is therefore important that high-quality annota-
tion for these model organisms is maintained, so that
genes and transcripts can be compared across these or-
ganisms consistently [136]. With the advent of CRISPR–
Cas9 technology, it is now possible to engineer specific
changes into model organism genomes to assess the ef-
fects of such changes on gene function [137].
Nevertheless, model organism genomes and human ge-
nomes differ. For example, the laboratory mouse is highly
inbred, whereas the human population is much more het-
erogeneous [138]. Furthermore, many environmental and
behavioral components are known to affect disease in cer-
tain mouse strains, which are factors that are not clearly
understood in human disease [139]. Although compara-
tive genomics helps to build good gene models in the hu-
man genome and understand gene function and disease,
basing predictions in clinical practice upon animal models
alone might lead to misdiagnosis.
New techniques to improve functional annotation
of genomic variants
NGS technologies facilitate improvements in gene anno-
tation that have the potential to improve the functional
annotation and interpretation of genomic variants. The
combination of both long and short NGS reads [140]
will change the scope of annotation. While short-read
RNA-Seq assays may be able to produce hundreds of
millions of reads and quantify gene expression, they are
generally unable to represent full-length transcripts,
which makes the assembly of such transcripts incredibly
difficult [141]. However, the greater read lengths pro-
duced by new sequencing technologies such as PacBio
and synthetic long-read RNA-Seq (SLR-Seq), which uses
Illumina short-read sequencing on single molecules of
mRNA, have the potential to produce sequence for
complete transcripts in a single read. In addition, utiliz-
ing longer-read technologies such as that from PacBio
has already been shown to improve resolution of regions
of the genome with SVs [142], and emerging technolo-
gies, such as 10X genomics [143], promise further im-
provements. This is especially important because WES is
unable to represent structural variation reliably. The im-
portance of representing such regions through WGS has
been demonstrated by numerous neurological diseases
associated with SVs, including cases of severe intellectual
disability [144]. Other examples of SV-induced neuro-
logical disease include Charcot–Marie–Tooth disease,which is most commonly caused by gene-dosage effects
as a result of a duplication on the short arm of chromo-
some 17 [145], although other causes are known [146];
Smith–Magenis syndrome, caused by copy-number
variants on chromosome 17p12 and 17p11.2 [147]; and
Williams–Beuren syndrome, caused by a hemizygous
microdeletion involving up to 28 genes on chromosome
7q11.23 [148].
Together, NGS data will also lead to the discovery of
new exons and splice sites that both extend and truncate
exons in a greater diversity of tissues and cell types.
Whether the variants identified that are associated with
novel exons or splice sites belong to protein-coding tran-
scripts, or potential regulatory transcripts, or are transcripts
likely to be targets of the NMD pathway, such technologies
will permit better functional annotation of these overlap-
ping variants. An example is the re-annotation of variants
that were previously called intronic as exonic sequences.
Similarly, a previously described synonymous substitution,
or benign non-synonymous substitution, could affect core
splice-site bases of a novel splice junction. RNA-Seq assays
are able to discern expression of individual exons, allowing
prioritisation of variants expressed in appropriate tissues
for a disease. In the future, clinical investigation could tar-
get the genome in conjunction with the transcriptome—for
example, using patient tissue as the basis for RNA-Seq
assays—to identify regions where genes are expressed
irregularly.
Transcriptomics datasets, such as CAGE [33], RAM-
PAGE [149] and polyA-seq [150], aid the accurate identifi-
cation of the 5′ (for the two former) and 3′ (for the latter)
ends of transcripts. This knowledge allows researchers to
better annotate the functionality of a biotype, specifically
enabling the addition of CDS where this was not previ-
ously possible, and enriching the functional annotation of
overlapping variants. Furthermore, knowledge of termini
allows the confident annotation of 5′ and 3′ UTRs that
could harbor important regulatory sequences such as
uORFs and miRNA target sites.
Other datasets, such as mass spectrometry (MS) [151]
and ribosome profiling (RP, or Riboseq) [152], indicate
translation, either by directly identifying proteins (MS) or
by identifying translation on the basis of ribosomal bind-
ing to mRNA transcripts (RP), which aids the accurate
identification of the presence and extent of expression of
the CDS. Combining these datasets with cross-species
conservation of protein coding potential found by Phy-
loCSF [153] allows annotators to identify previously unan-
notated protein-coding loci and confirm lncRNAs as
lacking in protein-coding potential.
With the increasing importance of epigenetics and its
role in neurological disorders [154], such as epilepsy
[155], several companies are making detection of these
features a priority—for example, detecting methylated
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[156]. Other well-described genetic marks are the DNase
hypersensitivity sites that are often found in regions of
active transcription [63]. However, before these marks
are considered in the process of annotation, we will re-
quire better experimental datasets that validate them. To
put such marks into context and aid validation, gene an-
notation must be as accurate and comprehensive as pos-
sible so that potential cis (local) and trans (distant)
interactions can be identified. Regulatory regions such as
enhancers are features that can be described as part of
the extended gene and represent the next frontier for
gene annotation using data such as Capture Hi-C [157]
and ChIA-PET [158] to identify physical connections be-
tween regulatory regions affected by variation and the
genes they regulate, which can often be located a great
distance away. This could mean that variants that were
previously considered to be benign could in future be re-
classified as pathogenic. For example, variants in evolu-
tionarily conserved transcription factor binding sites are
believed to have a role in narcolepsy [159].
Computational and manual genome-annotation methods
that have been described have relied almost exclusively on
traditional transcriptional evidence to build or extend
models of genes and their transcripts. While the number of
sequences in public databases continues to increase, genes
expressed at very low levels, or with restricted expression
profiles (such as many non-coding loci), are likely to remain
either under-represented or incomplete when relying on
such evidence [160, 161].
New technologies and software will help assess the
complexity of loci much more thoroughly through the
investigation of alternative splicing/translation start
sites/poly(A) sites [162], alternative open reading frames,
and so on. They will also allow the revisiting of the hu-
man genome—for example, to investigate evolutionarily
conserved regions and regulatory features for functional-
ity and to identify new non-coding loci structures as well
as new coding transcripts.
Conclusions
We have reviewed how important regions of the genome
that harbor pathogenic sequence variation can lie outside
the CDS of genes. We have discussed how researchers can
better understand why an incorrect interpretation of a
pathogenic variant could arise. Such reasons can range
from the human reference genome being incomplete, not
all exons being represented in public databases, to incor-
rect annotation of transcripts/exons owing to their expres-
sion in a different tissue or at a different developmental
stage to the disease phenotype. Table 4 gives a summary
of such examples. As such, considerable efforts continue
to be made to increase the catalogue of new genes in-
volved in diseases, such as neurological disease [127].However, even well-studied genes should be revisited itera-
tively to identify novel features that previous technology
could not detect. For example, a recent publication by Dje-
mie and colleagues [163] revisited patients who had pre-
sented with Dravet syndrome, typically associated with
SCN1A variants, but had been SCN1A variant-negative after
clinical sequencing. By re-testing with NGS, it was possible
to identify 28 variants that were overlooked with Sanger se-
quencing. Around 66% of the reported false-negative results
were attributed to human error, whereas many of the others
were a result of poor base-calling software [164].
It is important to remember that the full human tran-
scriptome has yet to be annotated across all tissues of the
human genome. Clearly, while gene panels and whole-
exome sequences are a great start to getting a diagnosis,
they are not perfect as they are snapshots of sequence at a
particular point in time, meaning that pathogenic se-
quence variants that lie in yet-to-be-annotated exons will
not be detected. This emphasizes the power of whole-
genome sequences as, unlike exomes, they can be re-
analysed again at any point in the future as new gene
structures are found [165]. To identify such features, it
will be important to update the annotation of disease
genes using the most relevant experimental methods and
tissue to help identify transcripts that might be expressed
at low levels or only at certain developmental stages.
Similarly, improvements in the understanding and an-
notation of gene structures can lead to reclassification of
variants as less pathogenic than previously believed, with
implications for treatment strategies. For example, de la
Hoya and colleagues demonstrated that improvements to
understanding of native alternative splicing events in the
breast cancer susceptibility gene BRCA1 show that the
risk of developing cancer is unlikely to be increased for
carriers of truncating variants in exons 9 and 10, or indeed
other alleles that retain 20–30% tumour-suppressor func-
tion, even where such variants had been previously char-
acterized as pathogenic [166].
Accordingly, it is essential to consider multiple transcripts
for pathogenic variant discovery, unlike the standard clin-
ical approach of only considering a ‘canonical’ transcript, in-
variably based on the longest CDS but not necessarily on
any expression values [167]. Such situations could result in
ambiguous HGVS nomenclature when transcript IDs are
not specified, and, as a result, important variants might be
missed if variant analysis is only performed against the ca-
nonical transcript. For example, a variant can be classified
as intronic based on the canonical transcript but could be
exonic when based upon an alternatively spliced transcript.
Such technical challenges illustrate the difficulties for clini-
cians when dealing with clinical reports containing details
of identified variants (for example, HGVS identifiers) and
attempting to map them accurately to function and allow
variant interpretation.
Table 4 Important areas to consider for genome annotation
Genome assembly is not complete Human assembly is still not complete and still being refined
The current assembly is GRCh38, which still contains fragmented genes, and gene duplications are
incorrectly represented, yet most analysis is still performed on GRCh37
Transcriptome is still incomplete Some exons are still not represented in the human genome owing to low expression or temporal
expression in tissue that has not yet been interrogated
WES kits will not contain all exons
WGS-negative cases should be iteratively re-analysed as new transcriptional features are revealed
Reference annotation datasets can be
missing key features
Automatic annotation is fast but not as accurate as manual annotation
CCDS—missing UTRs
LRG—single, usually canonical, transcript—potential for missing exons; choice of transcript is arbitrary
RefSeq—based on transcriptome, potential for missing exons and problems with inconsistent mapping
to reference assembly
Annotation does not necessarily determine which transcripts are the most likely to be functional, and the
longest one might not be the major one
Non-coding genome Long-range gene interactions are poorly understood; methods such as Capture Hi-C will provide insights
into such epigenetics
Previously ignored transcript biotypes such as NMD and retained intron are now known to have
important regulatory roles in disease
Non-coding RNAs have an important role in disease, yet they are hard to predict and their function
remains largely unknown.
Biotype associations A biotype conflict in annotation datasets will cause incorrect variant calls—for example, lncRNA variant
compared with coding gene, coding gene compared with pseudogene
Transcript expression profile Is transcript expressed in correct tissue for disease phenotype?
Is transcript expressed at the right developmental time for disease phenotype?
CCDS Collaborative Consensus Coding Sequence project, lncRNA long non-coding RNA, LRG Locus Reference Genomic project, NMD nonsense-mediated decay,
WES whole-exome sequencing, WGS whole-genome sequencing
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high-confidence transcripts and call variants against these
transcripts, highlighting variants that might have severe
effects against one or more such transcripts. To improve
sensitivity, these findings could be weighted by transcriptFig. 8 The importance of multiple alternative transcripts for variant interpretatio
how the same variant could have different outcomes in different transcripts. We
when there are multiple transcripts for a gene, this can have an effect on amino
combinations, meaning that the same exon in two different transcripts can hav
amino acid sequence. Note too that the untranslated region is represented by o
purple boxes represent the CDS of the nonsense-mediated decay (NMD) transcri
the following hypothetical variants. (1) NM_000000001.99(AGENE):c.2041C > T (p
an exon that is not expressed in brain. (2) NM_000000002.99(AGENE):c.4002 + 24
variant is intronic, yet, by looking across other transcripts, it is clear that the varia
NC_000000003.99:g.66178947G > T. This variant is intronic to the canonical trans
ENSP0000000004.1(AGENE):p.Gly276Ala. This variant falls in an exon that induces
potentially relevant to the clinician. Generally, NMD transcripts have been consid
such exons are now known to have an important role in gene regulation. For e
conserved exon in SNRPB that induces NMD can result in severe developmentaexpression level in the disease-relevant tissue(s) (Fig. 8).
To improve sensitivity even further, RNA-Seq assays from
different developmental stages could be interrogated to
see whether exons are expressed at the correct develop-
mental stage as that of the disease phenotype [63].n. This hypothetical example of gene ‘AGENE’ expressed in brain highlights
illustrate this further using hypothetical HGVS nomenclature. Note that
acid numbering of variants as different transcripts can have different exon
e a different translation and can also result in different lengths for the
range boxes. Green boxes represent the coding sequence (CDS), whereas
pt. Lines that join exons represent introns. Asterisks indicate the positions of
.Arg681Ter). This variant might not be of interest to the clinician as it lies in
51G > C. The Human Genome Variation Society (HGVS) suggests that this
nt falls in an extended coding exon that is expressed in brain. (3)
cript, but falls in a well-conserved exon that is expressed in brain. (4)
NMD. The exon is well conserved and expressed in the brain, making it
ered to be non-coding and excluded from sequence analysis. However,
xample, Lynch and colleagues [194] reported that variation in the highly
l disorders
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be implicated in a specific disease are now thought to
have insufficient evidence for their role in disease. For
example, the following genes were previously thought to
be associated with epilepsy: EFHC1 [168], SCN9A,
CLCN2, GABRD, SRPX2 and CACNA1H [169]. The Epi-
lepsy Genetics Initiative (EGI) attempts to address such
problems by iteratively re-analysing WES and WGS of
epilepsy cases every 6 months.
The overwhelming amount of sequence variation that
is generated by WES and WGS means that many vari-
ants produced will have no role in disease. Therefore,
the use of databases that contain sequence variants from
global sequencing projects, such as ExAC [170] and the
1000 Genomes Project [171] can help filter out common
variants to help identify rare variants [60, 172]. Such da-
tabases can be used to identify those genes that are in-
tolerant of any variation in their sequence, and, when
variants in such genes are identified in patients, this
could be an indicator of pathogenic sequence variation
[173]. Other variant databases, such as The Human
Gene Mutation Database (HGMD) [174] and ClinVar
[175], provide information on inherited disease variants
and on relationships between variants and phenotype.
Genomic interpretation companies are now providing
increasingly quick pathogenic variant interpretation
turnaround times [176–179]. However, the value of such
interpretation will only be as good as the gene annota-
tion that is used for genome analysis and interpretation,
demonstrating the need for continual updating and im-
provement of current gene sets.
Genome annotation is also increasingly seen as essen-
tial for the development of pharmacological interven-
tions, such as drug design. Typically, drug design targets
the main transcript of a gene (the choice of such a tran-
script is not necessarily informed by biological data, but
is generally based upon the longest transcript), yet, as
mentioned previously, it is now understood that certain
transcripts can be expressed in different tissues, or at
certain developmental times [180]. For example, the
onconeural antigen Nova-1 is a neuron-specific RNA-
binding protein, and its activity is inhibited by paraneo-
plastic antibodies. It is encoded by NOVA1, which is
only expressed in neurons [181]. The alternative splicing
of exon 5 of the epilepsy-associated gene SCN1A gener-
ates isoforms of the voltage-gated sodium channel that
differ in their sensitivity to the anti-epileptic medications
phenytoin and lamotrigine [180]. Finally, isoform switch-
ing in the mouse gene Dnm1 (encoding dynamin-1), as a
result of alternative splicing of exon 10 during embry-
onic to postnatal development, causes epilepsy [182].
With new drugs having a high failure rate and associ-
ated financial implications [183–185], it is not unreason-
able to suggest that identifying tissue-specific exons andtranscripts through annotation has the potential to re-
duce such failure rates significantly. New methods of
generating genomic data must therefore be adopted con-
tinually and interrogated by annotators to facilitate the
translation of genomic techniques into the clinic in the
form of genomic medicines.
Such advances will begin to address some of the con-
troversies and challenges for clinicians that the fast ad-
vances in genomics bring. They will help to understand
why current technology can fail to identify the patho-
genic basis of a patient’s disorder, or, more worryingly,
why it can produce an incorrect result where the wrong
variant is labelled as causative. This understanding will
help clinicians to explain the advantages and limitations
of genomics to families and healthcare professionals
when caring for patients. The implication is that it will
empower them to request reanalysis of unsolved cases as
newer technology improves the annotation of gene
structure and function. It will also encourage clinicians
to request referral for disease modification when therapy
becomes available for a clinical disease caused by spe-
cific genomic alterations.
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